Objective: This study was carried out to clarify the effects of the antidepressant fluoxetine, a selective serotonin reuptake inhibitor, for its potential use in autoimmune diseases like multiple sclerosis in a rat model of experimental autoimmune encephalomyelitis (EAE). Methods: The rat EAE model was induced by subcutaneous injection of guinea pig spinal cord homogenate. Rats received fluoxetine via daily intragastric administration, starting 2 weeks prior to immune induction (fluoxetine pretreatment). Clinical scores and pathological changes in EAE rats were analyzed. Changes in serum cytokine levels were assessed by ELISA. Results: Fluoxetine pretreatment significantly promoted remission in EAE. Histologically, fluoxetine-induced neuroprotection was accompanied by reductions in inflammatory foci and in the degree of demyelination in the spinal cord of EAE rats. The increase in serum IFN-γ in the EAE model was also suppressed by fluoxetine administration. Conclusions: These findings suggest that the prophylactic use of fluoxetine can relieve symptoms during remission in the acute EAE model, and these neuroprotective effects are associated with its anti-inflammatory effects.

Keywords:
Antidepressants, Cytokines, Experimental autoimmune encephalomyelitis, Fluoxetine, Multiple sclerosis
1.
Garrison GD, Levin GM: Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 2000;34:10–14.
2.
Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002;5:401–412.
3.
Fazzino F, Urbina M, Cedeno N, Lima L: Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4+ and CD8+ subpopulations and interleukins 2 and 4. Int Immunopharmacol 2009;9:463–467.
4.
Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK: Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009;87:1037–1045.
5.
Lassmann H, Bruck W, Lucchinetti CF: The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210–218.
6.
Hemmer B, Archelos JJ, Hartung HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291–301.
7.
McFarland HF, Martin R: Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8:913–919.
8.
Monteyne P, Van Antwerpen MP, Sindic CJ: Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. Acta Neurol Belg 1999;99:11–20.
9.
Navikas V, Matusevicius D, Soderstrom M, Fredrikson S, Kivisakk P, Ljungdahl A, Hojeberg B, Link H: Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 1996;64:63–69.
10.
Antel J, Owens T: Multiple sclerosis and immune regulatory cells. Brain 2004;127:1915–1916.
11.
Olsson T: Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995; 144:245–268.
12.
Codarri L, Fontana A, Becher B: Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 2010;23:205–211.
13.
Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH: T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010;162:1–11.
14.
Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK: Animal models of multiple sclerosis – potentials and limitations. Prog Neurobiol 2010;92:386–404.
15.
Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C: T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406–412.
16.
Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732–741.
17.
Cyranowski JM, Marsland AL, Bromberger JT, Whiteside TL, Chang Y, Matthews KA: Depressive symptoms and production of proinflammatory cytokines by peripheral blood mononuclear cells stimulated in vitro. Brain Behav Immun 2007;21:229–237.
18.
Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F, Kriwin P, Mendlewicz J: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006;21:219–225.
19.
Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J: Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008;79:1027–1031.
20.
Wei ZS, Hong MF, Su QX, Wang XH, Yu QY, Peng ZX, Zhang MX, Jie A, Wang R, Huang YQ: Super-high-dose methylprednisolone does not improve efficacy or induce glucocorticoid resistance in experimental allergic encephalomyelitis. Neuroimmunomodulation 2011;18:28–36.
21.
Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H: Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998;95:675–680.
22.
Sobel RA, Blanchette BW, Bhan AK, Colvin RB: The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ. J Immunol 1984;132:2393–2401.
23.
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755–1761.
24.
O’Connell PJ, Wang X, Leon-Ponte M, Griffiths C, Pingle SC, Ahern GP: A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 2006;107:1010–1017.
25.
Duszczyszyn DA, Beck JD, Antel J, Bar-Or A, Lapierre Y, Gadag V, Haegert DG: Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clin Exp Immunol 2006;143:305–313.
26.
Lees JR, Cross AH: A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. J Clin Invest 2007;117:297–299.
27.
Owens T, Wekerle H, Antel J: Genetic models for CNS inflammation. Nat Med 2001;7:161–166.
28.
Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B: Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006;129:1306–1318.
29.
Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988;140:1506–1510.
30.
Gillman PK: A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59:1046–1051.
31.
Pilgrim JL, Gerostamoulos D, Drummer OH: Deaths involving serotonergic drugs. Forensic Sci Int 2010;198:110–117.
32.
Bergstrom RF, Lemberger L, Farid NA, Wolen RL: Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry Suppl 1988;3:47–50.
33.
Park Y, Oh SJ, Chung DH: CD4(+)CD25(+) regulatory T cells attenuate hypersensitivity pneumonitis by suppressing IFN-gamma production by CD4(+) and CD8(+) T cells. J Leukoc Biol 2009;86:1427–1437.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.